Sutro Biopharma held its 2024 Annual Meeting of Stockholders and approved the election of directors, ratification of the appointment of Ernst & Young LLP as the independent registered public accounting firm, approval of executive compensation, and approval of an amendment to the Employee Stock Purchase Plan.